These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31160043)

  • 1. Adrenal insufficiency secondary to topic clobetasol.
    Bertholle-Gil J; Gil-Palmer A; Nicolau-Ramis J
    Med Clin (Barc); 2020 Apr; 154(8):324-325. PubMed ID: 31160043
    [No Abstract]   [Full Text] [Related]  

  • 2. Adrenal suppression following low-dose topical clobetasol propionate.
    Stoughton RB
    J R Soc Med; 1988 May; 81(5):308. PubMed ID: 3385719
    [No Abstract]   [Full Text] [Related]  

  • 3. Clobetasol--a potent new topical corticosteroid.
    Med Lett Drugs Ther; 1986 Jun; 28(715):57-9. PubMed ID: 3520267
    [No Abstract]   [Full Text] [Related]  

  • 4. Adrenal suppression following low-dose topical clobetasol propionate.
    Ohman EM; Rogers S; Meenan FO; McKenna TJ
    J R Soc Med; 1987 Jul; 80(7):422-4. PubMed ID: 3656312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate.
    Young CA; Williams IR; MacFarlane IA
    Br J Clin Pract; 1991; 45(1):61-2. PubMed ID: 1931550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenal insufficiency secondary to inappropriate oral administration of topical exogenous steroids presenting with hypercalcaemia.
    Bhatti RS; Flynn MD
    BMJ Case Rep; 2012 Jun; 2012():. PubMed ID: 22729340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clobetasol propionate and betamethasone-17,21-dipropionate with reference to adrenal suppression.
    Eriksen K
    Acta Derm Venereol; 1979; 59(4):372-4. PubMed ID: 92159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cushing's syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse?
    Güven A; Gülümser O; Ozgen T
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1173-82. PubMed ID: 18183788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of value and risks of external treatment with clobetasol-17-propionate (Dermovate)].
    van der Harst LC; Smeenk G; Burger PM; van der Rhee HJ; Polano MK
    Ned Tijdschr Geneeskd; 1978 Feb; 122(7):219-23. PubMed ID: 345134
    [No Abstract]   [Full Text] [Related]  

  • 10. Cushing's syndrome caused by topical steroid therapy for psoriasis.
    Abma EM; Blanken R; De Heide LJ
    Neth J Med; 2002 Apr; 60(3):148-50. PubMed ID: 12164372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
    Kimball AB; Gold MH; Zib B; Davis MW;
    J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical corticosteroids and secondary adrenal insufficiency: a relationship in the shade.
    Márquez Pardo R; Pérez Pelayo M; Aragoneses Calvo A; Gallego Rodriguez S; Martínez Barbeito MB
    Endocrinol Nutr; 2013 Nov; 60(9):e19-20. PubMed ID: 24076040
    [No Abstract]   [Full Text] [Related]  

  • 13. Topical clobetasol-17-propionate: review of its clinical efficacy and safety.
    Olsen EA; Cornell RC
    J Am Acad Dermatol; 1986 Aug; 15(2 Pt 1):246-55. PubMed ID: 3528243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.
    Katz HI; Lindholm JS; Weiss JS; Shavin JS; Morman M; Bressinck R; Cornell R; Pariser DM; Pariser RJ; Weng W
    Clin Ther; 1995; 17(3):390-401. PubMed ID: 7585843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergic contact dermatitis to topical corticosteroids: clobetasol propionate and clobetasone butyrate.
    Dooms-Goossens A; Vanhee J; Vanderheyden D; Gevers D; Willems L; Degreef H
    Contact Dermatitis; 1983 Nov; 9(6):470-8. PubMed ID: 6653104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenal insufficiency and diabetes mellitus secondary to the use of topical corticosteroids for cosmetic purpose.
    Sobngwi E; Lubin V; Ury P; Timsit FJ; Gautier JF; Vexiau P
    Ann Endocrinol (Paris); 2003 Jun; 64(3):202-4. PubMed ID: 12910062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clobetasol-induced milia.
    Iacobelli D; Hashimoto K; Kato I; Ito M; Suzuki Y
    J Am Acad Dermatol; 1989 Aug; 21(2 Pt 1):215-7. PubMed ID: 2768571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent topical treatment of psoriasis with clobetasol propionate ("Dermovate").
    Svartholm H; Larsson L; Frederiksen B
    Curr Med Res Opin; 1982; 8(3):154-7. PubMed ID: 6751703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of a pilot study investigating the potential of salivary cortisol measurements to detect occult adrenal suppression secondary to steroid nose drops.
    Patel RS; Wallace AM; Hinnie J; McGarry GW
    Clin Otolaryngol Allied Sci; 2001 Jun; 26(3):231-4. PubMed ID: 11437848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function.
    Katz HI; Hien NT; Prawer SE; Mastbaum LI; Mooney JJ; Samson CR
    J Am Acad Dermatol; 1987 Apr; 16(4):804-11. PubMed ID: 3553247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.